Differentiated Thyroid Carcinoma After <sup>131</sup>I-MIBG Treatment for Neuroblastoma During Childhood: Description of the First Two Cases

Santen, Hanneke M van; Tytgat, Godelieve A.M.; Wetering, Marianne D. van de; Eck-Smit, Berthe L. F. van; Hopman, Saskia; Steeg, Alida F. van der; Dijkum, Els J. M. Nieveen van; Trotsenburg, A S Paul van

doi:10.1089/thy.2011.0464

Cited by 34 publications

(15 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Van Santen et al[97] reported 2 cases of subclinical PTC in neuroblastoma survivors treated with 131 I-MIBG 5 and 12 years earlier. In a follow-up study by the same group of investigators, non-palpable thyroid nodules (most being benign nodules <1 cm in size) were found in 9/16 (56%) survivors, including 2 cases of PTC [54].…”

Section: Radiation-induced Thyroid Diseasementioning

confidence: 99%

Thyroid Sequelae of Pediatric Cancer Therapy

Waguespack

2018

Horm Res Paediatr

View full text Add to dashboard Cite

The hypothalamic-pituitary-thyroid axis is a common site of unintended, acquired disease either during or after the treatment of cancer. Children treated with external radiation therapy are at the highest risk for developing a thyroid-related late effect, but thyroid dysfunction and second primary thyroid neoplasms can also occur after treatment with radiopharmaceutical agents such as ¹³¹I-metaiodobenzylguanidine. Increasingly recognized is the development of early thyroid dysfunction as an off-target consequence of the more novel cancer therapeutics such as the tyrosine kinase inhibitors and immune checkpoint inhibitors. Thyroid sequelae resulting from irradiation may manifest only after years to decades of follow-up, and their resultant clinical symptoms may be indolent and non-specific. Therefore, lifelong monitoring of the childhood cancer survivor at risk for thyroid disease is paramount. In this comprehensive review, the myriad thyroid adverse effects resulting from pediatric cancer treatment are discussed and an overview of screening and treatment of these thyroid sequelae provided.

show abstract

Section: Radiation-induced Thyroid Diseasementioning

confidence: 99%

Thyroid Sequelae of Pediatric Cancer Therapy

Waguespack

2018

Horm Res Paediatr

View full text Add to dashboard Cite

show abstract

“…Cases of exposure in the prenatal period and the resultant development of congenital hypothyroidism and thyroid nodules have been widely reported in the literature [2,3]. Thyroid cancer has been reported in two adolescents receiving radioactive MIBG therapy, and there has been only one publication reporting papillary thyroid carcinoma developing as a result of 131I therapy administered to the mother [4,5]. Here we report a case of hypothyroidism in the 11-year-old child of a mother receiving 131I therapy due to thyroid cancer.…”

Section: Introductionmentioning

confidence: 82%

“…However, data from nuclear accidents have shown an increase in cases of non-immune hypothyroidism and thyroid cancers among exposed individuals [1,6,7]. Thyroid cancer was reported to develop in two adolescents receiving 131I MIBG therapy for neuroblastoma [4]. Cases of congenital hypothyroidism and thyroid cancer have been reported to develop following intrauterine exposure [2,3].…”

Section: Discussionmentioning

confidence: 99%

Acquired Hypothyroidism in an Adolescent Associated with Radioactive Iodine-131 Therapy of the Mother

Serdaroğlu¹,

Pirgon²

2016

Ann Clin Anal Med

View full text Add to dashboard Cite

ÖzetÇocukların radyoaktif iyota maruz kalması sonucu hipotiroidi ve tiroid kanserleri gelişebilir. Bu yüzden özellikle küçük çocuk ve gebelerin bu tedaviyi alanlardan bir süre uzak tutulması gerekir. Literatürde bu tedaviyi alanlarda kendilerinin tedavi alması sonucu iki olgu ve annesinin aldığı tedaviden etkilenerek bir olgu olmak üzere toplam sadece üç tiroid kanseri geliştiren adolesan olgu mevcuttur. Bu olgu sunumunda, radyoaktif iyot tedavisi alan bir anneyle aynı ortamda yaşayan ve annesinin bu tedavisine bağlı olarak hipotiroidi gelişen 11 yaşındaki kız olgu sunulup, literatür bilgileri ışığı altında tartışılması planlandı. Anahtar KelimelerÇocuk; Hipotiroidi; Radyoaktif İyot AbstractHypothyroidism or thyroid cancer may develop in children as a result of exposure to radioactive iodine. Therefore, young children and pregnant women in particular should not be in close physical proximity to patients receiving this therapy. We found only three cases of adolescents developing thyroid cancer in the literature. Two were affected by radioactive iodine treatment of themselves and one was affected by treatment of the mother. Here we report on an 11-year-old girl living in the same environment as her mother, who was receiving radioactive iodine therapy. The girl developed transient hypothyroidism in association with her mother's treatment. We discuss the case in light of the literature.

show abstract

“…Thyroid cancer has also been reported after treatment with 131 -I-MIBG for neuroblastoma without neck irradiation and despite prophylaxis with potassium iodide [47]. Treatment with 131 -I-MIBG for neuroblastoma has more recently been shown to possibly be associated with POI [48].…”

Section: The Effect Of Radiotherapymentioning

confidence: 99%

Childhood Cancer Treatments and Associated Endocrine Late Effects: A Concise Guide for the Pediatric Endocrinologist

Chemaitilly

Sklar

2018

Horm Res Paediatr

View full text Add to dashboard Cite

Endocrine complications are frequently observed in childhood cancer survivors (CCS); in many instances, these complications develop months to years after the completion of cancer therapy. The estimated prevalence of endocrine late effects is 50% among CCS; the main risk factors are external beam radiation that includes key endocrine organs (the hypothalamus/pituitary, thyroid and gonads) and/or alkylating agents. Novel agents targeting tumor growth have increased the options available to a small number of patients albeit with the need for treatment over long periods of time. Some of these agents, such as certain tyrosine kinase inhibitors and immune system modulators have been shown to cause permanent endocrine deficits. This chapter offers a brief summary of the conventional treatment strategies for the most common cancers of childhood and a brief overview of the endocrine late effects most commonly associated with these exposures. The impact of targeted therapies on the endocrine system will also be discussed. The aim of this chapter is to provide basic guidance to the consulting pediatric endocrinologist in preparation for the clinical encounter with a CCS. A more detailed discussion of the management of specific endocrine late effects can be found in the other chapters in this series.

show abstract

Differentiated Thyroid Carcinoma After ¹³¹I-MIBG Treatment for Neuroblastoma During Childhood: Description of the First Two Cases

Cited by 34 publications

References 16 publications

Thyroid Sequelae of Pediatric Cancer Therapy

Thyroid Sequelae of Pediatric Cancer Therapy

Acquired Hypothyroidism in an Adolescent Associated with Radioactive Iodine-131 Therapy of the Mother

Childhood Cancer Treatments and Associated Endocrine Late Effects: A Concise Guide for the Pediatric Endocrinologist

Contact Info

Product

Resources

About

Differentiated Thyroid Carcinoma After 131I-MIBG Treatment for Neuroblastoma During Childhood: Description of the First Two Cases

Cited by 34 publications

References 16 publications

Thyroid Sequelae of Pediatric Cancer Therapy

Thyroid Sequelae of Pediatric Cancer Therapy

Acquired Hypothyroidism in an Adolescent Associated with Radioactive Iodine-131 Therapy of the Mother

Childhood Cancer Treatments and Associated Endocrine Late Effects: A Concise Guide for the Pediatric Endocrinologist

Contact Info

Product

Resources

About

Differentiated Thyroid Carcinoma After ¹³¹I-MIBG Treatment for Neuroblastoma During Childhood: Description of the First Two Cases